Abstract:Background & Aims: Chronic liver injury often results in the activation of hepatic myofibroblasts and the development of liver fibrosis. Hepatic myofibroblasts may originate from 3 major sources: hepatic stellate cells (HSCs), portal fibroblasts (PFs), and fibrocytes, with varying contributions depending on the etiology of liver injury. Here, we assessed the composition of hepatic myofibroblasts in multidrug resistance gene 2 knockout (Mdr2(-/-)) mice, a genetic model that resembles primary sclerosing cholangitis in patients. Methods: Mdr2(-/-) mice expressing a collagen-GFP reporter were analyzed at different ages. Hepatic non-parenchymal cells isolated from collagen-GFP Mdr2(-/-) mice were sorted based on collagen-GFP and vitamin A. An NADPH oxidase (NOX) 1/4 inhibitor was administrated to Mdr2(-/-) mice aged 12-16 weeks old to assess the therapeutic approach of targeting oxidative stress in cholestatic injury. Results: Thy1(+) activated PFs accounted for 26%, 51%, and 54% of collagen-GFP(+) myofibroblasts in Mdr2(-/-) mice at 4, 8, and 16 weeks of age, respectively. The remaining collagen-GFP(+) myofibroblasts were composed of activated HSCs, suggesting that PFs and HSCs are both activated in Mdr2(-/-) mice. Bone-marrow-derived fibrocytes minimally contributed to liver fibrosis in Mdr2(-/-) mice. The development of cholestatic liver fibrosis in Mdr2(-/-) mice was associated with early recruitment of Gr1(+) myeloid cells and upregulation of pro-inflammatory cytokines (4 weeks). Administration of a NOX inhibitor to 12-week-old Mdr2(-/-) mice suppressed the activation of myofibroblasts and attenuated the development of cholestatic fibrosis. Conclusions: Activated PFs and activated HSCs contribute to cholestatic fibrosis in Mdr2(-/-) mice, and serve as targets for antifibrotic therapy. Lay summary: Activated portal fibroblasts and hepatic stellate cells, but not fibrocytes, contributed to the production of the fibrous scar in livers of Mdr2(-/-) mice, and these cells can serve as targets for antifibrotic therapy in cholestatic injury. Therapeutic inhibition of the enzyme NADPH oxidase (NOX) in Mdr2(-/-) mice reversed cholestatic fibrosis, suggesting that targeting NOXs may be an effective strategy for the treatment of cholestatic fibrosis. (C) 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Deletion of Protein Kinase D3 Promotes Liver Fibrosis in Mice

Mir-301A-3p Promotes Hepatic Stellate Cells Activation and Liver Fibrogenesis Via Regulating PTEN/PDGFR-β.

PLK1 regulates hepatic stellate cell activation and liver fibrosis through Wnt/-catenin signalling pathway

Perturbation of Specific Signaling Pathways Is Involved in Initiation of Mouse Liver Fibrosis

C1q/tumor Necrosis Factor-Related Protein-3 Acts As a Target Treating Hepatic Fibrosis

LHPP deficiency aggravates liver fibrosis through TGF-β/Smad3 signaling

The glycolytic enzyme PFKFB3 drives kidney fibrosis through promoting histone lactylation-mediated NF-κB family activation

FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2

Deletion of GPR81 Activates CREB/Smad7 Pathway and Alleviates Liver Fibrosis in Mice

Loss of MLKL ameliorates liver fibrosis by inhibiting hepatocyte necroptosis and hepatic stellate cell activation

Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K/AKT/PDGF axis activation in male mice

Loss of Protein Kinase D2 Activity Protects Against Bleomycin-Induced Dermal Fibrosis in Mice

Piezo1 specific deletion in macrophage protects the progression of liver fibrosis in mice

Pyruvate Kinase M2 Regulates Fibrosis Development And Progression By Controlling Glycine Auxotrophy In Myofibroblasts

Activated Hepatic Stellate Cells and Portal Fibroblasts Contribute to Cholestatic Liver Fibrosis in MDR2 Knockout Mice

Elk-3 Contributes to the Progression of Liver Fibrosis by Regulating the Epithelial-Mesenchymal Transition

EP3 enhances adhesion and cytotoxicity of NK cells toward hepatic stellate cells in a murine liver fibrosis model

Sphingosine kinase 1 aggravates liver fibrosis by mediating macrophage recruitment and polarization.

Tgfb3 and Mmp13 regulated the initiation of liver fibrosis progression as dynamic network biomarkers

Chitinase 3‐like 1 deficiency ameliorates liver fibrosis by promoting hepatic macrophage apoptosis

Liver Proliferation Is an Essential Driver of Fibrosis in Mouse Models of Nonalcoholic Fatty Liver Disease